靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1976-09-29 |
A Phase I/II Study of VST-1001 (Dilute Fluorescein) for Lymphatic Mapping and Localization of Lymph Nodes Draining a Primary Tumor Site in Patients With Clinically Node Negative Breast Cancer
The purpose of this Phase 1 portion of this clinical research study is to find out what dose of dilute fluorescein is needed for a surgeon to best see important lymph nodes that need to be removed during surgery (a standard of care surgery referred to as a Sentinel Lymph Node Biopsy procedure) in patients diagnosed with breast cancer.
The purpose of the Phase 2 portion of this clinical research study is to find out if giving dilute fluorescein sodium in combination with a radiotracer (a drug that is radioactive) can help surgeons localize the lymph nodes that need to be removed in patients diagnosed by breast cancer.
100 项与 Vestan Ltd. 相关的临床结果
0 项与 Vestan Ltd. 相关的专利(医药)
100 项与 Vestan Ltd. 相关的药物交易
100 项与 Vestan Ltd. 相关的转化医学